Acurx Wins Korean Patent for DNA Polymerase IIIC Inhibitors, Expanding IP to Six Countries
Korean Intellectual Property Office granted Acurx Pharmaceuticals a patent covering compositions-of-matter and methods of use for its DNA Polymerase IIIC inhibitors, expanding its patent estate to six countries. Lead candidate ibezapolstat is set to begin Phase 3 registration trials in the U.S. and EU for oral C. difficile treatment.
1. Patent Grant Details
The Korean Intellectual Property Office issued Acurx Pharmaceuticals a patent covering compositions-of-matter, methods of use and pharmaceutical formulations for its DNA Polymerase IIIC inhibitor program. This addition brings the company’s granted patents to six jurisdictions—including the U.S., Israel, Japan, India, Australia and Korea—strengthening its global IP protection for ACX-375C.
2. Clinical Pipeline Update
Acurx’s lead DNA Pol IIIC inhibitor, ibezapolstat, is poised to enter pivotal Phase 3 registration trials in both the U.S. and EU for oral treatment of acute C. difficile infection. The company is also initiating a groundbreaking trial in patients with multiply recurrent CDI, aiming to establish a single-agent regimen for acute and recurrent cases.